QuantHealth, a pioneer in AI-driven clinical trial simulation, has received a strategic investment from Sanofi Ventures, the venture capital arm of global healthcare leader Sanofi. The investment, which brings QuantHealth’s total funds raised to $30 million, will accelerate the adoption of patient-level simulations and digital twin technologies in drug development.

QuantHealth’s platform enables pharmaceutical companies to simulate clinical trials virtually using real-world data, generating millions of digital twins to predict trial outcomes and optimise protocol design. By improving trial success rates, timelines, and cost efficiency, the technology aims to make clinical development more predictive and streamlined.

Orr Inbar, CEO and co-founder of QuantHealth, said the partnership positions the company to scale its impact: “Sanofi is at the forefront of digital transformation in pharma, and this relationship will help us bring more predictive, AI-driven approaches to clinical development.”

Cris De Luca, partner at Sanofi Ventures and new observer on QuantHealth’s board, added that the approach could transform how trials are designed and optimised. Emmanuel Frenehard, chief digital officer at Sanofi, noted that the collaboration aligns with Sanofi’s AI-first strategy, offering an opportunity to reimagine clinical trial design through simulation.

The investment and enterprise relationship highlight a shared commitment to advancing drug development through the responsible use of artificial intelligence in life sciences.